Login Register Cart 0
Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Biography

Meet the Co-Editor

Author(s): Mark S. Gold

Volume 11, Issue 1, 2022

Published on: 12 August, 2022

Article ID: e120822207443 Pages: 1

DOI: 10.2174/221155601101220812121121

[1]
Blum K, Khalsa J, Cadet JL, et al. Cannabis-induced hypodopaminergic anhedonia and cognitive decline in humans: Embracing putative induction of dopamine homeostasis. Front Psychiatry 2021; 12: 623403.
[2]
Blum K, Kazmi S, Modestino EJ, et al. A novel precision approach to overcome the “addiction pandemic” by incorporating genetic addiction risk severity (Gars) and dopamine homeostasis restoration. J Pers Med 2021; 12: 212.
[3]
Blum K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci 2021; 420.
[4]
Moran M, Blum K, Ponce JV, et al. High genetic addiction risk score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: An Open Clinical Pilot Trial. Mol Neurobiol 2021; 58(7): 3335-46.
[5]
Oesterle TS, Kolla B, Risma CJ, et al. Substance use disorders and telehealth in the COVID-19 pandemic era: A new outlook. Mayo Clin Proc 2020; 95(12): 2709-18.
[6]
Gold MS, Baron D, Bowirrat A, Blum K. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome? J Neurol Sci 2020; 418: 117137.
[7]
Wiss DA, Avena N, Gold M. Food addiction and psychosocial adversity: Biological embedding, contextual factors, and public health implications. Nutrients 2020; 12(11): 1-26.
[8]
Blum K, Cadet JL, Baron D, et al. Putative COVID- 19 induction of reward deficiency syndrome (RDS) and associated behavioral addictions with potential concomitant dopamine depletion: Is COVID-19 social distancing a double edged sword? Subst Use Misuse 2020; 55(14): 2438-42.
[9]
Swenson S, Blum K, McLaughlin T, Gold MS, Thanos PK. The therapeutic potential of exercise for neuropsychiatric diseases: A review. J Neurol Sci 2020; 412: 116763.
[10]
SiWDA Patterson. Gold M. Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations. J Neurol Sci 2020; 411: 116718.
[11]
Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. J Neurol Sci 2020; 411: 116728.
[12]
Blum K, Baron D, McLaughlin T, Gold MS. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS). J Neurol Sci 2020; 411: 116733.
[13]
Kolla BP, Oesterle T, Gold M, Southwick F, Rummans T. Infectious diseases occurring in the context of substance use disorders: A concise review. J Neurol Sci 2020; 411: 116719.
[14]
El Hayek S, Allouch F, Razafsha M, Talih F, Gold MS, Wang KK, et al. Traumatic brain injury and methamphetamine: A double-hit neurological insult. J Neurol Sci 2020; 411.
[15]
Haidar MA, Jourdi H, Haj HZ, et al. Neurological and neuropsychological changes associated with SARS-CoV-2 infection: New observations, New mechanisms. Neuroscientist. 2020; p. 1073858420984106.

Rights & Permissions Print Cite
Article Metrics
18
3
© 2024 Bentham Science Publishers | Privacy Policy